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Abstract.
Background: Amyloid PET (aPET) imaging could improve patient outcomes in clinical practice, but the extent of impact
needs quantification.
Objective: To provide an aggregated quantitative analysis of the value added by aPET in cognitively impaired subjects.
Methods: Systematic literature searches were performed in Embase and Medline until January 2017. 1,531 cases over
12 studies were included (1,142 cases over seven studies in the primary analysis where aPET was the key biomarker; the
remaining cases included as defined groups in the secondary analysis). Data was abstracted by consensus among two observers
and assessed for bias. Clinical utility was measured by diagnostic change, diagnostic confidence, and patient management
before and after aPET. Three groups were further analyzed: control patients for whom feedback of aPET scan results was
delayed; aPET Appropriate Use Criteria (AUC+) cases; and patients undergoing additional FDG/CSF testing.
Results: For 1,142 cases with only aPET, 31.3% of diagnoses were revised, whereas 3.2% of diagnoses changed in the
delayed aPET control group (p < 0.0001). Increased diagnostic confidence following aPET was found for 62.1% of 870
patients. Management changes with aPET were found in 72.2% of 740 cases and in 55.5% of 299 cases in the control
group (p < 0.0001). The diagnostic value of aPET in AUC+ patients or when FDG/CSF were additionally available did not
substantially differ from the value of aPET alone in the wider population.
Conclusions: Amyloid PET contributed to diagnostic revision in almost a third of cases and demonstrated value in increasing
diagnostic confidence and refining management plans.
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INTRODUCTION
An accurate dementia diagnosis is crucial to opti-
mize effective patient management strategies. Recent
diagnostic criteria for Alzheimer’s disease and its
prodromal states now include measurement of at least
one biomarker to support clinical assessments [1–4].
The approval of 18F-labelled amyloid PET (aPET)
tracers—AmyvidTM (Eli Lilly, [5, 6]), NeuraceqTM
(Piramal Inc., [7, 8]), and VizamylTM (GE Health-
care, [9, 10])—in multiple countries worldwide from
2012 onwards, has meant that aPET has been increas-
ingly used in routine evaluation of patients with
cognitive impairment.
As part of regulatory approval processes for
aPET tracers, autopsy studies correlating tracer
uptake to pathologically detected amyloid demon-
strated sensitivities of 91–98% and specificities of
89–100% [11–14]. Previous aPET meta-analyses
focused on diagnostic accuracy relative to clinical
or pathological standards of truth [15–17]. Simi-
lar analyses have been conducted on other relevant
dementia tests, such as [18F]fluorodeoxyglucose PET
(FDG) [18, 19], cerebrospinal fluid (CSF) analy-
sis [18, 20], magnetic resonance imaging (MRI)
[18], and Mini-Mental State Examination (MMSE)
scoring [21].
This aggregated analysis expands on the recent
paper by Barthel and Sabri [22] who focused on
a high level qualitative overview of aPET utility
across individual studies. Here, the primary analy-
sis consolidates individual patient data from each
included study, generating deeper insight into diag-
nostic changes and clinical value added by aPET
in cognitively impaired subjects. Using as baseline
working diagnoses and management plans before
aPET scanning, aPET is analyzed in its utility as a tool
to aid differential diagnosis, diagnostic confidence
and patient management. Individual diagnostic tra-
jectories pre- to post-scan are also described for four
different patient groups relevant to the quantifica-
tion of aPET utility and include confidence intervals
to give an estimate of variability around the pooled
patient groups. The latter include the Appropriate
Use Criteria (AUC) patient group, recommended
jointly by the Alzheimer’s Association and the Soci-
ety for Nuclear Medicine and Molecular Imaging
[23, 24] and comprised only of cases where aPET
is specifically recommended (indeterminate persis-
tent mild cognitive impairment (MCI), atypical or
mixed disease presentation or atypically early age of
onset).
METHODS
Study identiﬁcation and selection
To classify for inclusion, studies had:
• A diagnostic and clinical utility analysis of aPET
imaging visually interpreted by pre-established
[5–10] dichotomization methods (i.e., amyloid
positive or negative).
• More than ten cognitively impaired patients.
• Pre-aPET working diagnoses based on symp-
toms, clinical history, neuropsychological test-
ing and/or structural imaging and without aPET.
• Post-aPET final diagnoses based on in vivo clin-
ical diagnostic criteria of the highest standards
available at the time of study execution [1–4,
25, 26]. Histopathological validation of the final
diagnoses was not reported in any aPET utility
study.
• A unique and sequential association between
aPET and post-aPET diagnosis. Post-aPET diag-
noses accompanied by FDG/CSF tests were
collected separately.
• A publication in peer-reviewed scientific jour-
nals or a conference presentation with peer-
reviewed abstract selection.
Search methods
The systematic search was carried out through
MEDLINE and EMBASE (both up to week 4
2017, Ovid interface) using 38 terms (Supplemen-
tary Table 1) to identify the included population
and disease type, imaging modality, tracers, clinical
utility terms and publication language (English). Ref-
erences within review articles were searched for any
additional papers (see Supplementary Figure 1 for
study selection flow). An additional, more focused
56-term literature search was performed by a second
blinded researcher for closer inspection of publi-
cations reporting utility measures and as reported
in Supplementary Table 2 and Supplementary
Figure 2.
From both searches, studies selected for inclusion
were reviewed by two authors (E.F., A.C.) (Table 1).
Studies with overlapping cohorts were refined only
to include the largest studies. Authors were contacted
for clarifications when required. Studies excluded at
the final manual selection stage are listed in Sup-
plementary Table 3 with the relevant rationale for
exclusion.
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Table 1
Overall characteristics of the included studies and incoming patients
Study name Study Purpose of Type of care N Radiotracerd N Type of incoming Indeterminate Pre-scan Dx Tests other
designa studyb centerc sites casese cohort cohort included certainty (%)f than aPETg
Ishii [37] Prosp DxC, Conf 3y 1 PIB 233 Any No <100 His, NP, MR
Grundman [31] Prosp DxC, PM, Conf 2y 19 FBP 229 Any, Uncertain etiology Yesh <85 His, NP, CT/MR,
Sanchez-Juan [41] Retro DxC, PM 3y 1 PIB 140 Any, Uncertain etiology Yesh <100 NPCT/MR, FDGi
Mitsis [43] Prosp DxC 3y 1 FBP, PIB 30 Any, routine cohort Yes <100 His, NP, MR
Zwan [32] Prosp DxC, PM, Conf 3y 2 FMM 211 Early onset, MCI No <90 His, NP, MR
Boccardi [33] Prosp DxC, PM, Conf 3y 18 FBP 228 Any No 15–85 NP, CT, MR, FDG, CSF
Frederiksen [38] Retro DxC, Conf 2y & 3y 1 PIB 57 Uncertain etiology Yesh <100 NP, CT, MR, FDG, CSF
Ossenkoppele [34] Prosp Conf 3y 1 PIB 154 Any Yesh ≤100 His, NP, MR, FDGi
Pontecorvo [42] Prosp RCT DxC, PM 2y & 3y 57 FBP 600 Any Yes 15–85 n/a
Schipke [39] Retro, Quest PM, Conf Unclear 14 FBB 121 Any, hypothetical No <100 MR, CSF
Bensaidane [35] Prosp DxC, PM, Conf 3y 1 NAV 28 Any, atypical No <100 His, NP, MR, FDG
Weston [36] Prosp DxC, PM, Conf 3y 1 FBP 20 Any No 68 ± 16 NP, MR, CSF
aPET, amyloid PET; Dx, diagnosis. a) RCT, randomized controlled trial; Prosp, prospective; Retro, retrospective; Quest, questionnaire. b) DxC, change in diagnosis; PM, change in patient
management; Conf, change in diagnostic confidence. c) Secondary care centers (2y) visit patients with general geriatric, neurological or psychiatric issues. Tertiary centers (3y) are specialized
memory or dementia clinics. Unclear cases may involve either secondary or tertiary care centers. d) FMM, [18F]flutemetamol; FBP, [18F]florbetapir; FBB, [18F]florbetaben; PIB, [11C]PiB; NAV,
[18F]NAV4694. e) Selected cases were included in each type of aPET utility analysis and Group as detailed in the caption of each relevant Table. f) When not explicit, the incoming diagnostic
certainty inclusion criteria was inferred from the patient selection methods wording. g) His, clinical history; NP, neuropsychological tests; CT, structural computed tomography; MR, magnetic
resonance imaging. h) The traceability of indeterminate cases in these studies was partial and could only be accomplished in full for those cases undergoing diagnostic change toward AD. i) Adjunct
FDG is performed together with aPET between the initial and revised diagnosis.
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Fig. 1. Primary analysis of the diagnostic trajectories for patients without CSF or FDG-PET data available at the time of the pre-scan diagnosis
(Group 1). All included subjects were broadly classified into presumed AD, Non-AD or indeterminate as per Supplementary Table 6. Due
to the included studies’ reporting format, it was not possible to include cases that undergo the following trajectories: indeterminate-nonAD,
nonAD-indeterminate, indeterminate-indeterminate. Hence the only trajectory from indeterminate is indeterminate-AD. Each percentage
reported relates to the level above it. Dx, diagnosis. PET, amyloid PET. Color coding from Post-scan Dx onwards: Grey boxes: diagnoses in
line with aPET; Black boxes: diagnoses changed in line with PET, Light grey boxes: diagnoses changed or confirmed contradicting PET.
QUADAS
The methodological and reporting quality of the
individual studies selected was assessed with the 14-
question QUADAS tool [27, 28] adapted by two
investigators (E.F., A.C.) to suit this review (see Sup-
plementary Table 4). QUADAS was then applied
to each study independently by each investigator
and a consensus on scoring reached (Supplementary
Table 4). QUADAS was independent of the analysis
and not designed to weigh data [29, 30].
Analysis methods
A total number of 1,531 subjects from 12 studies
were considered for this aggregated analysis, focus-
ing on assimilating individual study data (rather than
summary study results of aPET utility) into quantita-
tive measures. All patients were broadly classified
into presumed AD, Non-AD or indeterminate as
per Supplementary Table 6. Of these, 1142 cogni-
tively impaired subjects from 7 studies with pre- and
post-aPET diagnosis, aPET scans and no FDG/CSF
testing were considered for the primary measure
(Fig. 1) and consisted of an aggregate analysis of
all included patients. A secondary analysis detail-
ing more in-depth patient diagnostic trajectories was
also performed (Table 2). This included patient-level
data processed into measures useful to draw compar-
isons between four patient groups from across all 12
studies. Additionally, data on both diagnostic con-
fidence (described in text) and patient management
impact (Table 3) was available from a proportion of
the studies reviewed and was synthesized insofar as
the granularity of reporting allowed.
The primary analysis assimilates all cases with
pre-aPET diagnoses based only on a combination
of clinical history, neurocognitive assessment and/or
structural imaging and a post-aPET diagnosis. Three
measures were calculated:
1.1 Post-aPET diagnoses in line with amyloid PET
status (as a percentage);
1.2 Post-aPET diagnoses in contradiction to amy-
loid PET status (as a percentage);
1.3 Post-aPET diagnoses changed due to amyloid
PET result (as a percentage).
A secondary more in-depth analysis of patient
diagnostic trajectories was performed on a set of
groups, defined based on the following patient or
pre-aPET testing characteristics.
1. Group 1 further analyses all subjects examined
in the primary analysis.
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Table 2
Secondary analysis of the diagnostic trajectories. 95% CI were calculated by the Clopper-Pearson method
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96.4) 
91.1% 
(87.8-
93.7) 
31.3% 
(28.6-34.0) 
2.1 - Consistency of post-
aPET diagnosis with aPET 
(95% CI)i 
98.8% 
(97.5-
99.5) 
13.6% 
(9.5-
18.7) 
1.2% 
(0.4-
2.5) 
86.4% 
(81.3-
90.5) 
18.5% 
(13.3-
24.8) 
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(7.0-
28.6) 
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(71.4-
93.0) 
11.2% 
(5.5-
19.7) 
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aPET diagnosis with aPET 
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100)
 
0.0% 
(0.0-
33.6) 
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(0.0-
9.0) 
100%
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28.6% 
(11.3-
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100%
(90.5-
100)
 
71.4% 
(47.8-
88.7) 
0.0% 
(0.0-
9.5) 
(before aPET disclosure, 95% CI)
Diagnostic trajectory is defined as confirmation or change of pre-aPET AD or Non-AD diagnosis in the post-aPET diagnosis. a) Pathophysiological tests include only aPET, FDG and CSF analysis. b) When
the aPET result was delayed, the re-diagnosis after 3 months was solely based on time-related changes (and thus acted as a control post-aPET diagnosis). c) For diagnostic change, AD change represents
change “away from AD”, i.e., to either Non-AD or indeterminate Dx. d) For diagnostic change, Non-AD change represents change “towards AD”, i.e., from either Non-AD or indeterminate to AD. Non-AD
confirmation only includes the Non-AD to Non-AD trajectory. e) 2.2 – Post-scan diagnoses in line with aPET: Percentage of initial AD/Non-AD cases where aPET results were followed through in the revised
diagnosis. f) 2.3 – Post-scan diagnoses changed in line with aPET: Overall percentage of cases that without the use of aPET would potentially result in a wrong diagnosis. g) Group 1 is comprised of 7 studies:
Ishii 2016, Grundman 2013 (including 20/229 undiscernible cases with FDG and 14/229 cases with CSF), Sanchez-Juan 2014 (only 6/140 cases without FDG), Mitsis 2014 (only 28/30 cases without FDG),
Zwan 2017, Boccardi 2016 (including some undiscernible cases with FDG and CSF), Pontecorvo 2016 (only 301/600 “information” cases). Analysis was also performed without Grundman 2013 and Boccardi
2016 where some cases (around 10–15% of total) with prior FDG and CSF remained undiscernible. In this case, out of 761 total patients, 499 (65.6%) had pre-Dx of AD and 262 (34.4%) had a Dx other
than AD (Non-AD or indeterminate). Out of the AD patients 355 (71.1%) had positive aPET, resulting in 349 (98.3%) AD confirmations. Instead, 144 (28.9%) had negative aPET, resulting in 125 (86.8%)
diagnostic changes away from AD. Out of the Non-AD and indeterminate patients, 100 (37.1%) had positive aPET, resulting in 79 (79.0%) diagnostic changes towards AD. Instead, 162 (61.8%) had negative
aPET, resulting in 162 (100.0%) Non-AD confirmations. Overall, the AD consistency was 95.0%, the Non-AD consistency was 92.0% and the maximal prevention of misdiagnosis was 26.8%. h) N subjects
excludes indeterminate subjects confirmed as indeterminate or converting to Non-AD, as not enough data was reported in the studies for these patients to be included. i) 2.1 – Consistency of post-aPET
diagnosis with aPET: Percentage of Pos/Neg PET cases with either confirmed or changed diagnosis vs. any diagnostic trajectory. j). Group 2 is comprised of 1 study: Pontecorvo 2016 (only 283/600 “control”
cases). Diagnostic trajectories indeterminate to indeterminate and indeterminate to Non-AD were not included. k) Group 3 is comprised of 5 studies: Ishii 2016 (only 66/233 cases with early onset dementia),
Grundman 2013 (only 61/229 cases with indeterminate diagnosis), Mitsis 2014 (only 13/30 AUC+cases), Zwan 2017 (all cases) and Pontecorvo 2016 (only 21/600 “information cases with indeterminate
diagnosis). Analysis was also performed for all patients with pre-Dx tests “FDG, CSF or none”. In this case, out of 420 total patients, 222 (52.9%) had pre-Dx of AD and 198 (47.1%) had a Dx other than AD
(Non-AD or indeterminate). Out of the AD patients 163 (73.4%) had positive aPET, resulting in 163 (100.0%) AD confirmations. Instead, 59 (26.6%) had negative aPET, resulting in 51 (86.4%) diagnostic
changes away from AD. Out of the Non-AD and indeterminate patients, 104 (52.5%) had positive aPET, resulting in 88 (84.6%) diagnostic changes towards AD. Instead, 94 (47.5%) had negative aPET,
resulting in 94 (100.0%) Non-AD confirmations. Overall, the AD consistency was 96.4%, the Non-AD consistency was 91.9% and the maximal prevention of misdiagnosis was 33.1%. l) Group 4 is comprised
of 3 studies: Mitsis 2014 (2/30 cases with FDG), Frederiksen 2012, Bensaidane 2016, and Weston 2016. m) All patients in Group 4 are AUC+due to the inclusion criteria in the included studies.
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2. Group 2 acted as control where the aPET scan
result was not disclosed during the 3-month
diagnostic assessment period. This served to
reveal the extent of diagnostic change indepen-
dent of aPET.
3. Group 3 only included subjects consistent with
the aPET Appropriate Use Criteria (AUC+).
4. Group 4 captured all cases where pre-aPET
diagnosis was based on CSF testing and/or
FDG in addition to the standard combination of
clinical history, neurocognitive assessment and
structural imaging.
The above groups were analyzed using three mea-
sures outlined below (calculations further outlined in
Table 2 caption):
2.1 Consistency of post-scan diagnosis with aPET
result. For each of four possible pre-scan
to post-scan diagnostic trajectories (e.g., AD
confirmed as AD or Non-AD changed to AD)
data is shown for both positive and negative
aPET scans (therefore 8 permutations reported
as percentages).
2.2 Post-aPET diagnosis in line with the aPET
result (includes those confirmed and those
changed) when pre-aPET diagnoses of either
AD or Non-AD were recorded (two measures,
2.2a and 2.2b, reported as percentages).
2.3 Post-aPET diagnoses changed due to amyloid
PET result because of the insight provided by
aPET (one measure reported as a percentage).
This measure is similar to that captured in 1.3
in the primary analysis but is recorded here for
all 4 patient groups.
Two measures of impact on confidence were used.
The first examined the extent of change in confi-
dence over the population for which quantitative data
was available (6 studies, 725 cases [31–36]) and the
second assessed the proportion of patients having a
diagnostic confidence increase (6 studies, 870 cases
[32, 33, 36–39]), further subdivided by aPET out-
come when reported (5 studies, 850 cases [32, 33,
37–39]).
The impact on patient management was assessed
according to overall management change (in terms
of changes in therapy, care plan or additional testing)
by aPET outcome and by the change in medications.
The same four groups as for the aPET impact on
diagnostic change were considered. Some studies dis-
criminated patient management by aPET outcome
only (7 studies, 1046 cases [31, 32, 35, 36, 39–41])
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whereas others (4 studies, 605 cases [31, 32, 35, 41])
split the analysis between positive and negative aPET
outcome.
Statistical analysis
Each measure of aPET utility had 95% confi-
dence intervals calculated (Clopper-Pearson method,
GraphPad Prism 7). Statistical significance between
groups of possible clinical interest (group 1 versus 2
and AD diagnostic rule-in versus rule-out) was ana-
lyzed by Pearson Chi-Square Tests on SAS V9.3.
RESULTS
Study characteristics
This review included 12 studies: nine prospec-
tive (8 open-label and one randomized to immediate
and delayed aPET result disclosure [42]), two ret-
rospective observational studies [38, 41], and a
questionnaire extension of a retrospective study [39]
(Table 1). The data for [42] was retrieved from a con-
ference poster which was later published in full with
no alteration of data [40].
Studies included cohorts of variable size and study
reporting format, including some with patient-level
data [32–34, 36, 37, 43] and others with summary
data [31, 35, 38, 41, 42].
Risk of bias within and across studies
The heterogeneity of cohorts included required
reclassification of patient diagnostic categories into
standardized groups (presumed AD, Non-AD and
indeterminate) by consideration of diagnostic guide-
lines [1] (Supplementary Table 6). Supplementary
Table 7 shows the diagnostic language used in each
study to include subjects, breakdown of subjects ful-
filling the AUC criteria and numbers of patients with
additional FDG or CSF testing. The presence within
standardized diagnostic groups of a mix of disease
stage (prodromal, SCI, MCI, established dementia),
age of onset (early, late), symptomatic presentation
(typical, atypical, mixed) and certainty of diagno-
sis (low to high) is acknowledged but its impact is
difficult to quantify with the limited data granularity
available to correlate to observed diagnostic changes.
Nevertheless, this underlying diversity is inherent
to populations observed throughout memory clinics,
allowing for a clinically relevant and current analysis
of the utility of aPET.
The less specialized the clinical setting, the higher
the proportion of patients with diagnostic uncertainty,
although study inclusion criteria mitigate this effect.
Similarly, studies involving an element of random-
ization, such as unselected consecutive patients [32,
33, 38, 43] or non-disclosure of aPET result during
the diagnostic assessment period [42], are less prone
to bias when assessing true aPET impact. Addition-
ally, the group analysis performed in the secondary
analysis is limited by the subjects in group 2 coming
from the same patient cohort [42] (this point is further
expanded in the discussion).
An assessment of study bias can be inferred from
QUADAS [27, 28] in Supplementary Table 4.
Quantitative analysis
Impact on diagnosis
Primary analysis: In 1142 patients undergoing
aPET and no FDG/CSF testing, the pre-scan work-
ing diagnosis was AD in 65.7%, Non-AD in 29.6%
and indeterminate in 4.7% of cases (Fig. 1). Among
presumed AD subjects, 68.7% were aPET-positive.
AD dementia was confirmed post-aPET in 98.8% of
these cases, while the diagnosis was changed in the
remaining 1.2% despite positive aPET. Among pre-
sumed Non-AD subjects, 60.1% were aPET-negative
and in all a Non-AD diagnosis was confirmed. All
indeterminate cases had positive aPET, and all diag-
noses were subsequently revised to AD (by inclusion
criteria, see caption to Fig. 1).
Amyloid PET results were incongruent with the
pre-aPET working diagnoses in 31.5% of the incom-
ing presumed AD cases and in 39.9% of Non-AD
cases, leading to a significantly higher (p = 0.0031)
AD diagnosis rule-out (86.4%) than AD rule-
in (74.1%). Interestingly, despite discordant aPET
results, the pre-aPET working diagnosis was con-
firmed in 13.6% of AD and 25.9% of Non-AD
cases.
Overall, 93.6% of final diagnoses reflect disease
pathophysiology suggested by aPET either by con-
firming the pre-aPET working diagnosis (62.3%) or
by a discordant aPET result supporting a change in
diagnosis (31.3%). A minority of cases (6.4%) had a
revised diagnosis inconsistent with amyloid status.
Secondary analysis: For the secondary analysis
(Table 2), comparisons between patient groups were
performed. No substantial difference in terms of the
influence of aPET on diagnosis was found for all
three outcome measures between group 1 (aPET only,
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all subjects), group 3 (AUC+ patients) and group 4
(aPET and CSF or FDG, AUC+ patients).
Comparison between group 1 and control group
2 where aPET results were withheld from clinicians
until after formulation of a revised diagnosis, allows
to compare time-related diagnostic changes in the
absence and presence of aPET. As a result (group
1 versus 2, Table 2):
• In the absence of the aPET data, the diagnosis
remains largely unchanged over time.
When aPET data is available and is discordant from
the pre-aPET diagnosis there is significant diagnostic
change. Two examples are described: in analysis mea-
sure 2.1 92.5% AD cases remain AD when negative
aPET result is withheld (control group 2), while when
negative aPET is disclosed (group 1) only 13.6% AD
cases remain AD. Conversely, when the Group 1 AD
cases have a negative scan, 86.4% of diagnoses are
changed to Non-AD, whereas in the control group the
change to Non-AD diagnosis over 3 months was only
7.5%.
• In the control group, the amyloid burden
revealed by aPET at the end of the 3-month
observation period is more frequently inconsis-
tent with the working diagnosis (see measure
2.1): in control group 2 the percentage of
cases having an AD/Non-AD/indeterminate
final diagnosis is unvaried irrespective of aPET
outcome, whereas with immediate disclosure
(group 1) these percentages vary depending on
aPET outcome.
• For both incoming presumed AD and Non-AD
cases there is high consistency with aPET com-
pared to when aPET results were withheld (see
measures 2.2a and 2.2b, both >91% for group 1
but only 56-71% for group 2).
• In the period when aPET results are withheld
there is only 3.2% change in pre-aPET working
diagnosis versus 31.3% when aPET is disclosed
(see measure 2.3).
Impact on diagnostic conﬁdence
The impact of aPET on diagnostic confidence was
assessed in descriptive summary terms due to vari-
ability of reported data. It is also recognized that
this measure may be subjective and dependent on
clinician expertise levels.
Overall, aPET raises diagnostic confidence by a
mean of 12.7 ± 35.3% (with a net decrease in con-
fidence being associated with negative aPET cases,
6 Studies, 725 cases [31–36]). Where specified, the
pre-aPET diagnostic confidence was modest (e.g.,
68% in Zwan et al. [32], 71% in Ossenkoppele et
al. [34]). Diagnostic confidence increases in a total
of 62.1% [95% CI 58.8%–65.3%] of 870 incoming
subjects, 6 studies [32, 33, 36–39]). An increase in
diagnostic confidence (25.7% of 850 cases, 5 stud-
ies [32, 33, 37–39]) occurs more often for patients
with positive aPET (both concordant and discor-
dant from pre-aPET working diagnoses; 71.4% [95%
CI 67.3%–75.3%] of cases) than for aPET nega-
tive patients (both concordant and discordant from
working diagnoses, 45.6% [95% CI 40.2%–51.2%]
of cases).
Impact on patient management
Results are described according to Table 3.
A) Changes in medication ranged between
24–34% in the three groups having aPET avail-
able with a similar percentage (22%) in the
control group with delayed aPET disclosure.
B) The overall combined management changes (in
terms of changes in therapy, care plan and addi-
tional testing) in both the AUC+ group (group
3) and wider cohort (group 1) were similar both
with positive aPET (52% and 54% respectively)
and negative aPET (39% and 45% respec-
tively). Lower management changes were found
in group 4, where aPET was combined with
CSF/FDG.
C) In some cases, management changes were
reported for all aPET results combined. These
ranged widely, e.g., 72% in the wider cohort
(group 1) down to 41% in group 4 where
aPET was combined with CSF/FDG. In the
control group, reported management changes
were 56% indicating propensity to change in
the absence of pathophysiological evidence.
DISCUSSION
This study is a systematic review and quantitative
aggregated analysis aiming to reach a consensus over
the extent of utility of amyloid brain PET imaging
across different radiotracers and cohorts of cogni-
tively impaired patients assessed in conditions close
to routine clinical practice. The aim is to generate
data which could support diagnostic decision-
making and possible future cost-benefit assessments.
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The systematic review primarily discusses the utility
of aPET though it is recognized that other tests
for measuring amyloid load such as CSF provide
an alternative opportunity to influence diagnosis
despite some current limitations of this technique
[20, 44–48].
Our primary analysis in 1,142 patients shows
that the adjunctive use of aPET (in absence of
CSF/FDG) leads to revision of up to 31.3% [95% CI
28.6%–34.0%] diagnoses by elucidation of disease
pathophysiology. Additionally, for 94.9% [95% CI
93.1%–96.4%] of these cases initially diagnosed with
AD and 91.1% [95% CI 87.8%–93.7%] of Non-AD
cases (measures 2.2a/2.2b, Table 2), aPET results are
consistent with the revised diagnosis, demonstrating
strong confidence in aPET for assisting diagnos-
tic decision-making. It is particularly noteworthy
that when aPET result disclosure is delayed rather
than immediate [42], the working diagnosis at the
end of the 3 month control period is much less
frequently consistent with the amyloid burden even-
tually revealed by aPET (measure 2.1, Table 2).
It is now understood that cognitive decline is antic-
ipated by alterations in normal molecular biomarker
patterns, with amyloid being the first majorly affected
[49]. In this context, frequent discordance between
pre-aPET working diagnosis and aPET result is
noteworthy and underscores the notion that earlier
amyloid imaging may valuably contribute to measur-
ing risk of future cognitive decline [50].
It is recognized that what constitutes sufficient
clinical utility in a practical setting varies by center,
clinician, clinical population, and the wider context.
However, the evidence in this aggregated analysis and
other reviews [22] indicates that in general aPET sup-
ports diagnostic change in as high as one out of three
patients, emphasizing a strong need for clinical prac-
tice to shift away from symptom-based diagnoses
and towards pathophysiologically-driven diagnoses
[1, 25]. Nonetheless, the extent of utility needed
to justify clinical adoption of this technique is a
complex matter that requires to consider both the ther-
apeutic implications and the wider health-economic
impact including care planning, hospitalization, addi-
tional clinical time and possible alternative diagnosis
methods available [51]. On the other hand, the
assessment of utility remains a subjective topic
which some have attempted to address by surveying
patient willingness-to-pay in a variety of diagnostic
scenarios [52].
There are small numbers of cases where the con-
firmed diagnosis is inconsistent with the etiology
suggested by aPET. These few cases show that
clinical symptoms consistent with Non-AD demen-
tias can still overrule positive PET amyloid status.
Amyloid-negative confirmed AD cases are likely
“Suspected Non-Alzheimer’s Pathology” (SNAP)
patients [53], increasingly recognized as a syn-
drome in their own right. Furthermore, negative
aPET results are significantly more useful in diag-
nostic decision-making than positive aPET results
(Fig. 1), confirming the primary use as an adjunct
test for ruling out AD as recommended by EU
and US regulators [5–10]. In itself, the negative
predictive value of aPET is highly impactful from
diagnostic management [54], financial [55, 56] and
patient well-being [57] standpoints. Nevertheless,
positive aPET maintains a substantial 74.1% util-
ity for ruling-in AD, which supports its use in
this function as anecdotally reported by others
[58, 59].
Regarding aPET positioning in the diagnostic
decision-making process, it is still widely debated
which test may most cost-effectively serve physicians
in determining an accurate diagnosis for cognitively
impaired subjects, particularly in early disease stages
[17, 19–21, 60–64]. If we examine the AUC+ patients
only, there is lack of substantial difference in aPET
utility between aPET alone and accompanied by
CSF/FDG (Table 2). This suggests that FDG and CSF
may not substantially alter the impact of aPET both
from a diagnostic and management perspective. Pos-
sible reasons for this observation could be the less
precise correspondence between FDG uptake pat-
terns and (particularly early) disease etiology [19, 49]
and/or the potentially non-linear association between
CSF and amyloid burden as the disease progresses
[47]. Additionally, data from Sanchez-Juan et al. [41]
in cognitively impaired subjects of uncertain disease
etiology indicated greater relative impact of aPET
than FDG when both were employed for diagnostic
decision-making (Supplementary Table 5). Compa-
rable results (albeit with less detail reported) were
observed by Ossenkoppele et al. [34]. This is partic-
ularly the case when imaging results are discordant
from pre-aPET diagnoses indicating that to maximize
the impact of investigative procedures it may be bene-
ficial for aPET to precede FDG. The patient outcome
benefits of making use of aPET rather than FDG as
a first-line test in certain cases has been previously
argued [19, 65]. In particular, aPET may be more
valuable in earlier stages of dementia pathogenesis,
when regional FDG uptake variations are less reveal-
ing of different pathological processes [65] despite
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this being a time when treatments may be most effec-
tive [66]. Moreover, it is worth highlighting that aPET
appeared most suitable when borderline CSF resulted
in equivocal amyloid status as analyzed in Weston
et al. [36].
As for patient management change, significant
increase (over 16% extra cases, Table 3) occurs
following amyloid PET, both compared to patients
with delayed aPET results and to those having
prior CSF/FDG. This suggests that the increase
in management changes is independent of time-
related disease progression and could be related
to increased diagnostic confidence associated with
pathophysiological evidence provided by aPET. The
availability of CSF/FDG (group 4) prior to aPET
could allow some triaging of the patient management
which decreases somewhat the impact of additional
aPET scanning. Positive aPET drives more man-
agement changes than negative aPET. Medication
changes were apparent both in the absence and
presence of aPET with similar levels seen in all
groups (approximately 22–34%). These results indi-
cate that even in the absence of pathophysiological
data there is a bias to treat despite medications ulti-
mately shown as inconsistent with the amyloid status
when revealed (Table 2, group 2). Earlier aPET
could therefore provide more informed medication
planning [41].
Regarding diagnostic confidence, this study found
an increase with both positive and negative aPET
results concordant with pre-aPET working diagno-
sis due to additional pathophysiological diagnostic
evidence. Conversely, discordant results had lower
impact on diagnostic confidence since often giving
rise to diagnostic changes. Overall, positive aPET
was associated with diagnostic confidence increases
in 25.7% cases more than negative aPET.
Clinical guidelines published in 2013 [23, 24] indi-
cated distinct patient categories where the use of
aPET is deemed appropriate (AUC+). However, the
analysis in this study indicates that subjects beyond
the AUC criteria (i.e., group 1) could benefit similarly
to those in the AUC+ group in terms of diagnostic
impact (group 3). This is corroborated by previous
reports by others [67–69] who have found post-aPET
diagnostic and treatment plan changes to be some-
what independent of age of onset and diagnostic
confidence. Additionally, three studies included in
this analysis [34, 35, 43] reported diagnostic confi-
dence increases in AUC+ patients and a noticeably
stronger impact in the management of AUC+ cases
in amyloid-positive (but not negative) patients. This
outcome-specific impact could be explained by the
enhanced understanding of disease etiology offered
by affirmative test results.
This analysis has some limitations. While neces-
sary to effectively analyze diagnostic changes with
respect to aPET, the reclassification of patient diag-
noses into standardized groups (AD, Non-AD and
indeterminate) by consideration of the latest diag-
nostic guidelines [1] lead to some loss of granularity.
The majority of studies assessed here are also sim-
ple observational studies with the diagnosis observed
before and after the aPET scan. The presence of a
single study [42] with a control cohort (i.e., no aPET
test considered between diagnoses) represents a lim-
itation which is recognized as a known issue and is
being addressed in new amyloid utility studies such
as AMYPAD [70]. Furthermore, the heterogeneity of
patient populations across individual studies could
affect the quantification of utility (Supplementary
Table 7 and Risk of Bias section in Methods). Given
the detail available in each paper, it is not possible
to quantify at this time how different patient groups
benefit from aPET, as this requires further research
to avoid speculative conclusions. This is particularly
the case for Non-AD aPET positives and cognitively
normals.
Conversely, the aggregation of this data inherently
displaying a variety routine practice patient groups
allows to quantify more broadly the value of aPET in
the general population visiting secondary and tertiary
centers and could be useful for cost-effectiveness
analyses and clinical decision-making.
Our observations in this analysis are based on the
post-aPET diagnosis as standard of clinical truth in
absence of histopathological verification as the ulti-
mate standard of truth. This may alter the figures
obtained from the true aPET impact. However, aPET
imaging and histopathological findings at autopsy
have been shown to correlate strongly with over
90% accuracy [5, 7, 9, 71] and this highly-powered
analysis has the advantage of reducing both physi-
cian, population and test selection biases, giving good
estimations of true aPET utility. Also, concordance
between diagnostic change after aPET and extent of
mismatch between clinical diagnosis and final neu-
ropathological diagnosis [72] indicates overall high
diagnostic performance of aPET. This analysis is also
not intended to examine the impact of CSF and FDG
as tests in their own right.
Analysis of the extent of impact of study-specific
population and test variations on aPET utility was
restricted by the limited detail available within the
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studies considered. Thus, the overall quantification
of aPET utility assumed all cases in this aggregated
analysis carry equal weight in reflection of the
inherent variability of cases incoming in routine
practices. Nonetheless, the consideration of indi-
vidual patient data represents an advancement from
Barthel and Sabri [22] where overall utility measures
are only based on summary results as calculated in
each individual study and then weighted according
to study power. Furthermore, the impact of aPET on
patient health, quality of life and institutionalization
remain a domain for further research. Finally, the
effect of medication and management changes on
longer term patient outcomes useful for reimburse-
ment discussions, is a subject that studies such as
IDEAS [73] and AMYPAD [70] aim to address.
Since this analysis has been performed other stud-
ies have come to light examining the utility of aPET.
Ceccaldi et al. [74] studied 205 subjects in a multi-
center tertiary memory setting where CSF testing
was not feasible or was equivocal. In this group of
subjects, the patients presented with complex clini-
cal features and a high degree of clinical uncertainly
and hence the change in diagnosis after aPET (in
this case [18F]florbetaben) was greater (66.8%) than
seen in the meta-analysis reported here. A further
[18F]florbetaben study of 507 subjects [75] examined
an unselected memory clinic cohort of equal numbers
of AUC and non-AUC subjects (for example subjec-
tive cognitive decliners) and reported similar levels
of diagnostic changes; 28% in the AUC and 23% in
the non-AUC group after the aPET scan further indi-
cating the consistency of data reported in our paper.
Conclusion
The data retrieved in this aggregated analysis
support the utility of aPET in diagnostic decision-
making, confidence of diagnosis and management
planning for patients with cognitive impairment.
The relative impact of aPET on diagnostic change
was >30%, consistent with the difference previously
reported by Beach et al. [72] between clinical and
post-mortem diagnoses. Additionally, the substan-
tial number of cases having diagnostic confidence
increases and management changes point to a broad
impact of aPET on patient outcomes.
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